18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. - Wikidata - awgldk - TriplyDB

18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.

18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.

http://www.wikidata.org/entity/Q41877778

about

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.Image registration for quantitative parametric response mapping of cancer treatment response Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.Antiangiogenic therapy for glioblastoma: current status and future prospects.Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.18F-fluorothymidine PET imaging in gliomas: an update.A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma Early prediction of treatment response in advanced gliomas with (18)F-dopa positron-emission tomography Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.Controlling escape from angiogenesis inhibitors.18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?A generalized parametric response mapping method for analysis of multi-parametric imaging: A feasibility study with application to glioblastoma.¹⁸F-fluorodopa positron-emission tomography: an emerging imaging modality for patients with brain metastases.18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas

P2860

Q26853308-12AA4463-659B-4EC0-B678-1AEC3B13F14C Q27342179-9275F028-1EB3-48E5-970C-5A36B9A96E4B Q30764736-63CE7C4E-EEBE-4639-AEFA-C0AF368FFDBA Q30794621-56BE5710-60D0-4F80-ADC8-9F007C87C3AC Q30810432-CDBCD877-E652-4B8A-BA3E-6A059B99363C Q34193723-F0065DAB-5389-40C7-9338-9DC6C050269A Q34348544-3CAE62D5-EEBE-4DFC-98AE-226A27E37872 Q34523319-6EEDC5A0-830C-48C1-AD0B-8364787D0DE2 Q35598954-70A7D88A-0DBD-4276-849F-B9FAF1A3D783 Q35895174-939BCFDB-F39B-435B-97DF-F3E71FFAC9DA Q36404866-3E026663-4417-4863-9C53-7197A6AA1EC6 Q37201450-A0F2DD79-AA2F-49D4-BD42-4AA2ACD5A113 Q37577677-2064BBEB-D129-4FDE-ABF1-22DB0810B6AD Q37641220-23DEEDFA-CF72-4CA7-A3E6-12F27AD42A91 Q37672654-C4ACFFD1-0F8C-4EC7-9D4B-15B6EC9ABE5C Q38403271-336B1DAD-B85E-4CEE-860C-9DB2BAF09B82 Q38786526-BBCBBA69-884E-4A4A-9A49-37606BCE8AFE Q38815396-E9673772-9D41-472A-B33C-94A48B28732C Q39022941-7EA441E7-DE68-4691-8E22-13526C7068A8 Q39031636-A941E3E3-A15F-4E30-A48E-BF7472652239 Q42234940-D5395E54-7AEA-40CF-857A-ED272FDEEFC7 Q47698896-D5A34D55-F05E-4EA9-B5D4-213197B1F3AF Q48737939-6C2C085F-5DBC-48EA-B1AB-E853861E462C Q52801683-728A56EE-6FDB-45F2-AA91-DE93CB65DC94 Q52950126-9A598C67-BC20-4535-96E4-0363FE69A83F Q57177114-DFF0D2AD-DE3E-4CDF-921D-D9D52E764818

P2860

18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.

http://www.wikidata.org/entity/Q41877778

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

18F-FDOPA and 18F-FLT positron ...... omas treated with bevacizumab.

@en

type

label

18F-FDOPA and 18F-FLT positron ...... omas treated with bevacizumab.

@en

prefLabel

18F-FDOPA and 18F-FLT positron ...... omas treated with bevacizumab.

@en

P1433

Q41877778-2B35002C-0DE8-4664-A7D5-6FD24A5A134D

P1476

Q41877778-AB5769A8-C5A3-4C11-9834-CF4660D1ECE1

P2093

Q41877778-30C86E8A-E153-47AA-8312-1BF55417B055

Q41877778-4AEC2E9F-09A0-4E1D-BD34-18529F939DF2

Q41877778-6CF38CC2-036E-4204-8671-B23199217160

Q41877778-6E2F66CD-3FC1-4673-B965-DEE22253AC83

Q41877778-748A2D8F-626B-4C02-BC37-1C35EF2DDB7C

Q41877778-764927AA-F6A3-4D85-9483-3FFC51F63C6C

Q41877778-7A60FD58-5579-42CC-AF7F-5289E8970C79

Q41877778-7DDBAAB2-F2A7-49A3-8524-AA9FB41104E6

Q41877778-D95E5A97-B164-4E50-A010-A6E728964B8D

Q41877778-F280BDD1-ED19-43EE-AF28-B3B3A8E7F31A

P2860

Q41877778-06917E2E-93DB-4671-B957-7AE7A703F526

Q41877778-0EA39590-DE5E-42CB-A004-7166E6593094

Q41877778-20070766-1828-4745-9AB4-765B4F4A665B

Q41877778-294CD5AF-CA0E-4673-91A7-19DADEF30F49

Q41877778-2A3C72F8-9BC3-4935-8B0F-D103A41F4249

Q41877778-34256E04-1BD9-4EA7-8F28-6908BF427C08

Q41877778-36F8A534-B3BA-40F6-8AEC-6013681EDC21

Q41877778-3CDCC8EA-A634-4593-AB1F-FCBC74907409

Q41877778-3D2AC3F9-5AE8-451B-9561-7599A88A3A64

Q41877778-3DD93B7A-BF09-4072-900B-A8C44B4BFFD2

P304

Q41877778-AB0291A9-9355-4472-8CF4-46C01F0D12F4

P31

Q41877778-0B15393B-3BD7-4CD2-92B2-731ED04EF756

P356

Q41877778-D94231AD-1DCF-465F-BAC0-3022F9914853

P433

Q41877778-7691B754-27AF-49FB-8F4D-D89BA45F4EFD

P478

Q41877778-EB717354-2E56-4E71-A45E-24D8F0E27693

P577

Q41877778-B49F88F4-661B-43CF-8581-95F2FB7F0348

P5875

Q41877778-D7ADEF17-0B96-484B-A733-C8A4ED4F5381

P698

Q41877778-C5F85C1D-623C-4861-A2C6-430EB64E8B88

P921

Q41877778-5CE8AC09-D866-45AB-988D-39BCEE30D04C

P932

Q41877778-8182CFE2-3C0C-4855-8D18-7689750592BA

P356

P1433

P1476

18F-FDOPA and 18F-FLT positron ...... omas treated with bevacizumab.

@en

P2093

Albert Lai

http://www.w3.org/2001/XMLSchema#string

Benjamin M Ellingson

http://www.w3.org/2001/XMLSchema#string

Johannes Czernin

http://www.w3.org/2001/XMLSchema#string

Michael E Phelps

http://www.w3.org/2001/XMLSchema#string

Phioanh L Nghiemphu

http://www.w3.org/2001/XMLSchema#string

Robert J Harris

http://www.w3.org/2001/XMLSchema#string

Taryar Zaw

http://www.w3.org/2001/XMLSchema#string

Timothy F Cloughesy

http://www.w3.org/2001/XMLSchema#string

Wei Chen

http://www.w3.org/2001/XMLSchema#string

Whitney B Pope

http://www.w3.org/2001/XMLSchema#string

P2860

Glioblastoma multiforme--treating a deadly tumor with both strands of RNA

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer

Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab

Imaging of gliomas.

P304

1079-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOS141

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227343480

http://www.w3.org/2001/XMLSchema#string

P698

22711609

http://www.w3.org/2001/XMLSchema#string

P921

P932

3408264

http://www.w3.org/2001/XMLSchema#string